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Abstract
Protein transduction domains (PTDs), such as the HIV1-TAT peptide, have been previously used to promote the uptake of
proteins into a range of cell types, including stem cells. Here we generated pancreatic transcription factors containing PTD
sequences and administered these to endoderm enriched mouse embryonic stem (ES) cells under conditions that were
designed to mimic the pattern of expression of these factors in the developing pancreas. The ES cells were first cultured as
embryoid bodies and treated with Activin A and Bone morphogenetic protein 4 (BMP4) to promote formation of definitive
endoderm. Cells were subsequently plated as a monolayer and treated with different combinations of the modified
recombinant transcription factors Pdx1 and MafA. The results demonstrate that each transcription factor was efficiently
taken up by the cells, where they were localized in the nuclei. RT-qPCR was used to measure the expression levels of
pancreatic markers. After the addition of Pdx1 alone for a period of five days, followed by the combination of Pdx1 and TAT-
MafA in a second phase, up-regulation of insulin 1, insulin 2, Pdx1, Glut2, Pax4 and Nkx6.1 was observed. As assessed by
immunocytochemistry, double positive insulin and Pdx1 cells were detected in the differentiated cultures. Although the
pattern of pancreatic markers expression in these cultures was comparable to that of a mouse transformed b-cell line (MIN-
6) and human islets, the expression levels of insulin observed in the differentiated ES cell cultures were several orders of
magnitude lower. This suggests that, although PTD-TFs may prove useful in studying the role of exogenous TFs in the
differentiation of ES cells towards islets and other pancreatic lineages, the amount of insulin generated is well below that
required for therapeutically useful cells.
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Introduction
Type 1 diabetes is an autoimmune disease, in which the b-cells
in the islets of Langerhans are specifically destroyed. The disease is
currently treated with multiple daily injections of insulin, however
it is very difficult using exogenous insulin to prevent hypogly-
caemic episodes and the debilitating late complications of the
disease. Islet transplantation may represent a potential form of
treatment [1], but the poor availability of donor tissue prevents its
widespread use. For this reason alternative sources of b-cells from
human pluripotent cells has been sought [2].
Most of the protocols that have been established to drive
pluripotent cells towards the b-cell lineage involve inducing the
formation of a definitive endoderm (DE) enriched population by
using Activin A [3,4], a member of the TGFb family of growth
factors. From there the cells are directed down a differentiation
pathway that mimics the events that occur in the developing
mouse [5]. The idea is to recapitulate the pattern of expression of
key transcription factors, including Pdx1, Ngn3, NeuroD, Nkx6.1,
Pax4, and MafA, that define the b-cell lineage [6]. This approach
has been validated by controlling the temporal expression of an
exogenous Pdx1 gene in ES cells that have been stably transfected
with a tetracycline responsive Pdx1 DNA construct [6]. This
ability to fine tune the activity of key transcription factors in a dose
and time dependent manner may overcome some of the challenges
in generating functional b-cells in vitro.
Most cells are designed to prevent non-specific uptake of
proteins. However, certain viruses have circumvented this by
generating proteins that contain protein transduction domains
(PTDs) [7]. Thus the PTD of the HIV1-TAT protein has been
exploited in cell engineering because of its effectiveness and small
size [8,9], and TAT-fused proteins have been shown to be
efficiently taken up by a variety of cells, including ES cells [10–12].
In the present study we used PTD-mediated uptake of Pdx1 and
MafA into DE-enriched mouse ES cells. These transcription
factors were added in a manner that mimicked the temporal
pattern of expression in the mouse embryo. The results showed
that insulin expressing b-like cells could be generated. However,
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observed for the differentiated ES cells, insulin expression levels
were very much lower when compared to those of the MIN-6 b-
cell line or human islets, suggesting that PTD-TFs may have
a limited role in protocols designed at generating ES-derived islet
cells for therapeutic purposes.
Methods
Cell Culture
HeLA cells (ATCC, Teddington, UK) were cultured in
Dulbecco’s Modified Medium (DMEM) containing 15% foetal
calf serum (FCS). The mouse CGR8 ES cell line [13] was cultured
on gelatin coated tissue culture dishes in medium composed of
KO- DMEM supplemented with 15% KO Serum Replacement,
16 nonessential amino acids, 16 L-glutamine, 1% b-mercap-
toethanol (all from Invitrogen, Paisley, UK) and leukemia
inhibitory factor (LIF). CGR8 differentiation was done in
chemically defined medium (CDM) [14] composed of Iscove’s
Modified Dulbecco’s Medium/F12, 16chemically defined lipids
(both from Invitrogen), 7 mg/ml insulin, 5 mg/ml BSA, 450 mM
monothioglycerol (all from Sigma, Dorset, UK), 15 mg/ml trans-
ferrin (Roche Diagnostics, West Sussex, England) in suspension
cultures for embryoid bodies (EBs) formation. For DE formation
cells were cultured as EBs in CDM supplemented with 100 ng/ml
Activin A and 10 ng/ml BMP-4 for 2 days and with Activin A
alone for another 4 days [6]. For pancreatic differentiation EBs
were plated in cell culture plates covered with Matrigel
TM. Cells
were then cultured for 21 days in KO-DMEM in the absence or
presence of 1 mM Pdx1 and/or TAT-MafA. MIN6 cells (ATCC,
Teddington, UK) were cultured in DMEM containing 25 mM
glucose supplemented with 15% FCS (both from Gibco) and
70 mM b-Mercaptoethanol (Sigma).
Human Islets
Human islets of Langerhans were obtained with appropriate
ethical approval in place. Upon arrival the fresh islet tissue was
stored in TrizolH reagent (Invitrogen) for subsequent RNA
extraction and RT-qPCR analysis.
Vector construction and protein purification
The His6-Pdx1 construct was generated by inserting the coding
sequence of human Pdx1 into a pQE-31 expression vector
(Qiagen, West Sussex, UK). The His6-TAT-MafA and the His6-
TAT-Pdx1 constructs were generated by inserting mouse MafA
and human Pdx1 coding sequences into a pET 28b TAT vector.
These constructs were used to transform the competent E. coli
strain BL21 (DE3) (Invitrogen). Transformed BL21 (DE3) cultures
expressing the protein of interest were used to inoculate 2 L of LB
medium supplemented with kanamycin and ampicillin and grown
for 1.5 h at 37uC (25uC for Pdx1 cultures). IPTG (isopropyl b-D-1
thiogalactopyranoside) was added to the cultures 4 h before
harvesting. Cell pellets were lysed in 8 M Urea, 0.1 M NaH2PO4
at pH 8.0 for 1 h. Cell debris was removed by centrifugation and
the cleared lysate was applied to a His-select affinity column
(Sigma) pre-equilibrated with lysis buffer. The column was washed
with 8 M Urea, 0.1 M NaH2PO4 at pH 6.3 and proteins were
eluted in 8 M Urea, 0.1 M NaH2PO4 at pH 4.5. Protein fractions
were diluted 406in 20 mM Tris pH 7.6, incubated overnight at
4uC and re-concentrated using a 10 kDa Amicon Centrifugal filter
unit (Millipore, Livingston, UK). Final protein concentration was
assessed with the Biorad protein assay.
SDS-PAGE and Western Blotting
Protein aliquots were diluted in NuPage Loading Buffer, run on
a 10%, 1 mm, Bis-Tris polyacrylamide gel (both from Invitrogen)
and stained with Coomassie Brilliant Blue. Gels used for
immunoblotting were transferred to a nitrocellulose membrane,
and probed with rabbit anti-Pdx1 antibody [6], 1:1000 or rabbit
anti-MafA antibody, 1:200 (Santa Cruz Biosciences, Heidelberg,
Germany). Subsequently, blots were incubated with a horseradish
peroxidase conjugated anti-rabbit IgG antibody (1:5000).
RT-qPCR
RNA was extracted using TrizolH reagent (Invitrogen). After
digestion with DNase I (Invitrogen) to remove any contaminating
DNA, 1 mg of RNA was used for cDNA synthesis. Quantitative
Polymerase Chain Reactions (RT-qPCRs) were then performed
using the TaqMan gene expression assays (Tables 1 and 2, Applied
Biosystems, Paisley, UK). Real-time PCR mixtures were prepared
as described by the manufacturer (SensiMiX, Bioline, London,
UK) for each gene, denatured at 95uC for 15 seconds and then
cycled at 95uC for 30 seconds, 60uC for 30 seconds and 72uC for
10 seconds during 50 cycles, followed by final extension at 72uC
for 10 minutes. QPCRs were run in a Roche Lightcycler 480H in
triplicate and normalized to GAPDH in the same run. Data was
normalized to mouse embryonic stem cells or untreated cells, using
the 2
2DDCT method [15]. Statistical analysis was performed using
One Way ANOVA.
Immunocytochemistry
Cells were washed in Phosphate Buffer Saline (PBS) and fixed in
4% paraformaldehyde (PFA). Permeabilisation was done by
Table 1. List of mouse TaqMan Gene Expression Assays used
for RT-qPCR.
Gene TaqManH Assay ID
Sox17 Mm00488363_m1
Sox7 Mm00776876_m1
Bry T Mm00436877_m1
Gsc Mm00650681_g1
Mixl1 Mm00489085_m1
Foxa2 Mm00839704_mH
Insulin 1 Mm01259683_g1
Insulin 2 Mm00731595_gH
Pdx1 Mm00435565_m1
MafA Mm00845209_s1
Ngn3 Mm00437606_s1
Pax4 Mm01159036_m1
IAPP Mm00439403_m1
NeuroD Mm01946604_s1
Nkx6.1 Mm00454962_m1
Glut2 Mm00446224_m1
Somatostatin Mm00436671_m1
Glucagon Mm00801714_m1
Albumin Mm00446224_m1
Gapdh Mm99999915_g1
Amylase Mm02342487_g1
doi:10.1371/journal.pone.0036481.t001
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followed by washing in PBS. Non-specific interactions were
blocked with 10% goat serum in Tris Buffer Saline with 0.01%
Triton X-100 (TBST) (Sigma). Cells were stained with rabbit anti-
Pdx1 (1:1000), rabbit anti-MafA (1:200), (both from Santa Cruz
Biosciences), guinea-pig anti-insulin (1:100, Abcam, Cambridge,
UK) or guinea-pig anti C-peptide (1:50, Abcam) overnight at 4uC.
Cells were then probed with goat anti-rabbit AlexaFluor 594
(1:400) or goat anti-guinea pig Alexa Fluor 488 (1:400, both from
Invitrogen). Cells were mounted in Vectashield with 49,6-
diamidino-2-phenylindole (DAPI, Vector Labs, Peterborough,
UK).
Immunohistochemistry
Embryoid bodies (EBs) were washed in PBS and fixed in 4%
PFA overnight at 4uC followed by embedding in 1% agarose prior
to paraffin embedding and sectioning. All sections were cut at
a5mm thickness. For immunofluorescent staining sections were
subjected to heat induced antigen retrieval for 15 min using Tris-
EDTA Buffer, pH 9.0 and blocked with 10% goat serum in
TBST. The samples were then incubated with primary antibodies
rabbit anti-Sox7 (1:100, Abcam) or rabbit anti-Sox17 (1:100,
Santa Cruz Biotechnology), overnight at 4uC. Sections were then
probed with anti-rabbit AlexaFluor 488 (1:400, Invitrogen) for 1 h
at room temperature. Slides were mounted in Vectashield with
DAPI (Vector Labs).
Results
Purification and Uptake of PTD-Transcription Factors
We have previously shown that mouse and human ES cells can
be directed towards an endocrine pancreatic lineage by regulating
the expression of the homeodomain transcription factor Pdx1 in
response to 49 hydroxytamoxifen added to the culture media [6].
In the present study we intended to determine whether the activity
of Pdx1 could be modulated by adding the transcription factor
directly to the cells. In addition, we would extend the study to
include the bZIP factor MafA, which plays a role in the late stages
of b-cell differentiation [16,17]. The approach involved generating
recombinant transcription factors that were engineered to contain
PTD sequences from the HIV1-TAT protein. This was achieved
by inserting the cDNAs corresponding to Pdx1 and MafA into
pET28b expression vectors, which contain the sequence of the
HIV1-TAT protein transduction domain. Given that the Pdx1
sequence already codes for an Antennapedia like protein trans-
duction domain [18], the Pdx1 sequence was also cloned into the
expression vector pQE-31, which does not contain the TAT
sequence (Fig. 1A). These three vectors were then amplified in
Escherichia coli BL21 (DE3), followed by purification of Pdx1, TAT-
Pdx1 and TAT-MafA by histidine affinity chromatography. The
purity of the proteins obtained was assessed by SDS-PAGE
(Fig. 1B), and the identity of each transcription factor confirmed
by Western Blotting and Mass Spectrometry (data not shown). To
determine the ability of the purified proteins to translocate into
mammalian cells, each protein was added to the culture medium
of HeLa cells to a final concentration of 1 mM. Nuclear uptake of
the transcription factors was found to be time dependent, with
a maximum of nuclear protein detected after addition of the PTD-
transcription factors to the cells for a period of 5 hours. No major
difference was detected in Pdx1 and TAT-Pdx1 uptake by the
HeLa cells after the 5 hour period (Fig. 1C). For this reason, and
because TAT-Pdx1 appeared to be subjected to higher amounts of
degradation during the purification procedure (Fig. 1B), the
subsequent studies were carried out with Pdx1 rather than TAT-
Pdx1.
To determine whether Pdx1 and TAT-MafA could be
efficiently taken up into mES cells, each protein was added to
the mES culture media for a period of 4 hours. After this
incubation period, both transcription factors were detected in the
cells by immunostaining, with 63.7611.7% and 23.866.1% of cell
nuclei positive for Pdx1 and TAT-MafA, respectively. Neither of
these transcription factors was detected in untreated mES cells
(Fig. 1D, E), indicating that mouse ES cells do not endogenously
express Pdx1 or MafA. Collectively these results indicate that
recombinant Pdx1 and TAT-MafA are able to directly translocate
into the nuclei of mES cells.
Activin A and BMP-4 Induce Definitive Endoderm
formation in mESCs
In the mouse, the pancreas develops from the definitive
endoderm [19]. Activin A as a surrogate for Nodal signalling acts
as the master inducer of definitive endoderm formation (DE) in
culture [3]. It has also been shown that BMP-4 is necessary for
promoting DE formation by inducing the formation of the
intermediate layer mesendoderm, while Activin A further induces
DE differentiation [6]. In this study a similar approach was used to
derive DE from mES cells. Undifferentiated mES cells were
cultured as embryoid bodies (EBs) for 2 days in chemically defined
medium (CDM) containing BMP-4 and Activin A to induce
mesendoderm formation. After this period, the EBs were cultured
in CDM containing Activin A alone for another 4 days (Fig. 2A).
Mesendoderm markers Mixl1 and Gsc were up regulated at day 4
of the differentiation protocol, suggesting that at this stage an
intermediary mesendoderm population was being generated. At
day 4 the DE markers Sox17 and Foxa2 were already highly up-
regulated, indicating that some of the cells had already reached the
definitive endoderm differentiation stage. A stronger up-regulation
of these endoderm markers was observed at the final stage of the
differentiation protocol (day 6), accompanied by the down-
regulation of the mesendoderm markers Mixl1 and Gsc, suggest-
ing that more cells in the culture had undergone the transition
from mesendoderm to DE (Fig. 2B). This protocol generated an
endoderm enriched cell population, which was characterized by
the up-regulation of the definitive endoderm markers Sox17 and
Foxa2, while the mesoderm marker Brachyury T and the
extraembryonic endoderm marker Sox7 were not detected in
treated cells (Fig. 2B). These results were confirmed at the protein
Table 2. List of human TaqMan Gene Expression Assays used
for RT-qPCR.
Gene TaqManH Assay ID
Insulin Hs00355773_m1
Pdx1 Hs00236830_m1
MafA Hs01651425_s1
Ngn3 Hs00360700_g1
IAPP Hs00169095_m1
NeuroD Hs00159598_m1
Nkx6.1 Hs00232355_m1
Glut2 Hs00165775_m1
Somatostatin Hs00174949_m1
Glucagon Hs00174967_m1
Gapdh Hs99999905_m1
doi:10.1371/journal.pone.0036481.t002
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either day 4 or day 6 in treated cells, while non treated EBs
presented high expression levels of this marker (Fig. 3, top panel).
The endoderm marker Sox17 was detected in both non treated
and differentiated cells at day 4, however at the end of the
differentiation protocol nearly all cells were positive for Sox17 in
DE enriched EBs, while non treated cells had lost the expression of
the DE marker (Fig. 3, bottom panel). These results indicate that
a DE enriched population was efficiently generated after Activin A
and BMP-4 treatment.
It was important to determine whether the DE-enriched
population of cells would be able to take up the recombinant
PTD Transcription Factors (PTD-TFs) from the culture medium.
To do this, DE enriched EBs were plated in culture dishes covered
with Matrigel
TM and allowed to attach for a period of 5 days. On
the fifth day of culture the cells were incubated with 1 mM of Pdx1
Figure 1. Purification and cellular uptake of TAT-MafA, Pdx1 and TAT-Pdx1. (A) Schematic representation of TAT-MafA, Pdx1 and TAT-Pdx1
protein sequences. The PTD box represents the Antennapedia-like protein transduction domain of Pdx1. An histidine tag (His6) was added to the
sequence of each protein for binding to the affinity column. (B) The purity of recombinant TAT-MafA, Pdx1 and TAT-Pdx1, was assessed on
a polyacrylamide gel stained with Coomassie Brilliant Blue. (C) Western blot analysis was performed on nuclear (N) and cytoplasmic (C) extracts after
incubation of HeLa cells for 1, 3 or 5 hours with 1 mM recombinant Pdx1, TAT-MafA or TAT-Pdx1. (D) Immunocytochemistry with anti-Pdx1 and anti-
MafA antibodies of mES cells incubated for 4 hours without (N/A) or with (PTD-TF) 1 mM recombinant Pdx1 or TAT-MafA. Inlets of individually stained
cells are shown. Nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI). (E) Total and nuclear protein uptake was assessed by
counting the positive cells from triplicate cultures, where n=300 cells/replicate. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0036481.g001
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with specific MafA or Pdx1 antibodies revealed that over 80% of
cells were positive for either Pdx1 or MafA (Fig. S1), while non-
treated DE-enriched EBs did not express any of the pancreatic
transcription factors. These results indicated that the PTD-TFs are
also efficiently taken up by ES cells differentiated towards
definitive endoderm, thus establishing the conditions necessary
for mimicking their expression during pancreatic development.
PTD-Transcription factors drive DE progenitors towards
insulin-producing cells
To differentiate further the mES cells from DE towards the b-
cell phenotype, the recombinant transcription factors Pdx1 and
TAT-MafA were administered to the cells in a way that mimics
pancreatic development observed in vivo. It is known that during
pancreatic development Pdx1 is expressed in a biphasic manner,
in which the first wave of Pdx1 expression is necessary to specify
Figure 2. Generation of a Definitive Endoderm enriched population from mouse ES cells. (A) Protocol for generation of definitive
endoderm (DE) in mouse embryonic stem (mES) cells. Cells were cultured as embryoid bodies in chemically defined medium and treated for 2 days
with 100 ng/ml Activin A (A) and 10 ng/ml BMP4 (B), and for the following 2 or 4 days with Activin A alone. (B) Treated (B+A) and non treated (N/A)
cells were harvested at days 2, 4 and 6 of the differentiation protocol and expression of definitive endoderm (Sox17 and Foxa2), extraembryonic
endoderm (Sox7), mesendoderm (Mixl1 and Gsc) and mesoderm (Bry T) markers was determined by RT-qPCR. Data represent the average of triplicate
experiments and are expressed as mean 6 SEM. Data are expressed as gene expression relative to Gapdh and normalised against day 0 mouse
embryonic stem cells (mESCs), where p,0.05 (*), p,0.01(**) or p,0.001 (***).
doi:10.1371/journal.pone.0036481.g002
Protein Transduction in Pancreatic Differentiation
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36481the pancreatic domain in the primitive foregut [20,21], while the
second wave of Pdx1 expression drives the further differentiation
of b-cells [22]. In order to simulate this process in vitro, the DE
enriched cells were first plated in cell culture dishes and allowed to
attach for 5 days. Subsequently, the cells were cultured in the
absence or presence of 1 mM Pdx1 for a 5 day period and, again in
a second phase, from day 15 to 21 (Fig. 4A). In the second phase of
treatment, TAT-MafA was added simultaneously with Pdx1 in
order to recapitulate the expression pattern observed during in vivo
pancreatic development. To determine whether at this later stage
Pdx1 or MafA alone would be able to drive the cells towards the b-
cell phenotype, these transcription factors were also independently
added to the culture (Fig. 4A). After 21 days in culture in the
presence of the PTD transcription factors the differentiated cells
were harvested and their mRNA levels analysed by RT-qPCR
(Fig. 4B). When Pdx1 was added to the culture medium only once,
from day 5 to day 10, no pancreatic or liver markers were up-
regulated when compared to cells that were not treated with PTD-
proteins, suggesting that the first wave of Pdx1 expression was not
sufficient to promote formation of b-cells or the pancreatic domain
in vitro. Similar results were obtained when Pdx1 or TAT-MafA
were added independently to the culture during the second
expression wave that should drive the formation of b-cells (Fig. 4B).
However, when both Pdx1 and TAT-MafA were added
Figure 3. Differentiated DE cells do not express extraembryonic markers. Embryoid Bodies (EBs) were treated with Activin A (A) and BMP4
(B) for a 6 day period. Sections of treated and untreated EBs were made at days 4 and 6 of the differentiation protocol. (A) Top panels (a–d) show
sections obtained from treated (A+B) and untreated (N/A) EBs stained for the extraembryonic marker Sox7. Bottom Panels (e–i) show counterstaining
with the nuclear marker DAPI. (B) Top panels (a–d) show sections obtained from treated (A+B) and untreated (N/A) EBs stained for the definitive
endoderm marker Sox17. Bottom Panels (e–i) show counterstaining with the nuclear marker DAPI. Data are representative of triplicate experiments.
doi:10.1371/journal.pone.0036481.g003
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and 2 genes was observed, as well as the endogenous b-cell
transcription factors Pdx1, Nkx6.1, Pax4, NeuroD and the
transporter Glut2 (Fig. 4B). Along with the expression of these
b-cell markers, other endocrine pancreatic markers were in-
creased, such as the d-cell marker somatostatin and the exocrine
cell marker amylase (Fig. 4B). The fact that the endocrine
precursor Ngn3 was decreased in the cells treated with Pdx1 and
TAT-MafA is in keeping with the fact that mature beta cells lose
the expression of this precursor after differentiation [23]. The liver
marker albumin was also up-regulated after this treatment
(Fig. 4B), suggesting that a mixed population of cells was obtained,
with both liver and pancreatic phenotypes present.
In order to characterize further the phenotype of the cells
obtained after the treatment with the combination of PTD-TFs,
immunocytochemistry was performed to assess whether the b-cell
markers insulin and Pdx1 were present at the protein level (Fig. 5).
Double positive insulin and Pdx1 producing cells were detected in
cells treated with the combination of Pdx1 and TAT-MafA (P+M
cells), while neither insulin nor Pdx1 was detected in cells grown in
the absence of the transcription factors. In order to assess whether
the detected insulin was being produced de novo by the
differentiated cells, staining for C-peptide was performed (Fig. 6),
confirming that insulin was being produced by the cells and not
taken up from the media. C-peptide staining was observed in
83.0%610.6 (n=3) of the treated cultures, indicating that the
majority of the cells in culture were differentiated towards the b-
cell lineage.
There were a number of interesting features when the pattern of
expression of markers in P+M cells was compared with RNA
extracted from mouse MIN6 b-cells and human islets (Fig. 7). The
MIN6 and P+M cells expressed higher levels of insulin 2 than
insulin 1, with roughly equivalent relative levels of Pdx1, Ngn3,
NeuroD and Nkx6.1 and relatively higher levels of MafA and the
transporter Glut2 in P+M cells. The same was true when P+M
cells were compared with human islets, which being a mixed cell
population expressed high levels of the somatostatin, glucagon and
IAPP. The fact that these were expressed at levels substantially
lower than insulin 1 and 2 in P+M cells suggested that the PTD-
TF mediated differentiation was preferentially directed towards b-
cells. However, the striking observation was the extremely low
levels of insulin mRNAs in the P+M cells compare to that in the
MIN6 cells or human islets.
Figure 4. Pdx1 and TAT-MafA promote pancreatic differentiation of DE-enriched mouse ES cells. (A) Diagram of the different
differentiation culture conditions. After definitive endoderm (DE) formation mES cells were plated as a monolayer and treated for 21 days with the
indicated combinations of Pdx1 (P) and TAT-MafA (M). (B) On day 21 cells were harvested and total RNA was extracted for analysis of the expression
of pancreatic genes by RT-qPCR. Data represent the average of triplicate experiments and are expressed as mean 6 SEM. Data are expressed as gene
expression relative to GAPDH and normalised against untreated (N/A) cells, where p,0.05 (*), p,0.01 (**) or p,0.001 (***).
doi:10.1371/journal.pone.0036481.g004
Figure 5. PTD-TF transduced ES cells co-express Pdx1 and insulin. Immunocytochemistry of untreated (N/A) cells or cells treated with Pdx1
from day 5 to 10 and with a combination of Pdx1 and TAT-MafA from day 15 to 21 (P+M). Top panels show staining for the nuclear marker DAPI,
Insulin and Pdx1 in untreated cells (a–c). Middle panels show individual staining of DAPI, Insulin and Pdx1 in P+M treated cells (d–f). After treatment
with P+M, Pdx1 was detected in the cells nuclei (g, h), while insulin was present in the cytoplasm (g, i). Data are representative of triplicate
experiments.
doi:10.1371/journal.pone.0036481.g005
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Advances in islet transplantation [1], albeit limited [24], have
been hindered by a dependence on the availability of cadaveric
tissue, and stimulated a drive towards generating a replenishable
supply of islets from human pluripotent cells. Despite huge
progress in the differentiation of embryonic stem (ES) cells towards
pancreas, it has been impossible at this stage to generate a fully
functional b-cell in vitro, i.e. one that secretes meaningful amounts
of insulin in response to glucose in the physiological concentration
range [2]. The in vitro differentiation of pluripotent cells towards
pancreatic lineages is dependent on the addition to the culture
media of growth factors and small molecule inhibitors that
recreate cell signaling events that occur in the developing embryo.
These signaling pathways intersect within the nucleus to establish
transcriptional networks that change during the course of
development. The importance of these networks was emphasized
in our previous study, in which we used a tetracycline-regulatable
system to control the activity of an exogenous Pdx1 gene. Thus
subtle changes in its temporal expression had a significant effect on
the developmental outcome [6]. At present it is possible to
generate pancreatic progenitors that can further differentiate into
islet-like structures following engraftment in immunocompromised
mice [25]. The in vivo environment can therefore recapitulate the
conditions necessary to establish these networks. We surmised
therefore that some of the challenges in generating functional b-
cells in vitro might be overcome by adding exogenous transcription
factors directly to the culture medium.
PTD-TFs have previously been used to study the developing or
regenerating pancreas. Thus, administration of a TAT-Ngn3
fusion protein to cultured E9.5 and E13.5 pancreatic explants
resulted in efficient uptake and nuclear localisation and an
increased level of endocrine differentiation compared to control
samples [26], while intraperitoneal injection of recombinant Pdx1
into streptozotocin diabetic mice restored euglycaemia through
a combination of b-cell regeneration and liver reprogramming
[27]. Here we show that the levels of intracellular Pdx1 can be
manipulated by adding Pdx1 protein directly to the culture media.
When used in combination with a PTD-MafA protein, we were
able to differentiate DE-enriched mES cells towards a population
of cells that co-expressed Insulin and endogenous Pdx1, and
expressed some of the phenotypic characteristics of a b-cell. The
outcome was dependent on adding Pdx1 in two spatially separated
phases and the presence of both Pdx1 and PTD-MafA in the
second phase.
Although in the present study we were able to detect Insulin
mRNA and protein by immunocytochemistry, the levels were
below the sensitivity of our C-peptide and insulin assays.
Importantly, however when P+M cells were compared with
MIN6 b-cells and human islets, although some similarities were
found, there were sufficient differences to suggest that additional
TFs such as Ngn3, NeuroD and Pax4 that have been shown to
play an important role in reprogramming towards islet cells
[28,29] might be required to induce the formation of a more
mature b-cell population. Importantly, the levels of expression of
insulin mRNA was small when compared to those found in MIN6
Figure 6. Insulin is synthesized de novo by PTD-TF transduced
ES cells. After the 21 day differentiation protocol, untreated (N/A) and
cells treated with Pdx1 from day 5 to 10 and with a combination of
Pdx1 and TAT-MafA from day 15 to 21 (P+M) were stained with a C-
Peptide antibody and nuclei counterstained with DAPI. An inlet (b) of
a higher magnification is shown in treated samples (d and f). Data are
representative of triplicate experiments.
doi:10.1371/journal.pone.0036481.g006
Figure 7. Expression profile of pancreatic markers in PTD-TFs Transduced ES cells, the MIN6 b-cell line and in human islets.
Comparison of expression levels between the mouse b-cell line MIN6, human islets and CGR8 cells treated with the combination of Pdx1 and TAT-
MafA (P+M). The expression levels of the different markers was analysed by RT-qPCR. Data represent the average of triplicate cultures and are
expressed as mean 6 SEM relative to GAPDH.
doi:10.1371/journal.pone.0036481.g007
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expressing cells within the P+M population, but this is unlikely
since the immunocytochemistry indicated a very even pattern of
expression throughout the culture. Although we have shown that
the majority of the differentiated ES cells were driven towards
insulin producing cells, low mRNA levels of the liver marker
albumin were also detected in our cultures. Pancreas and liver
share a common endodermal origin and the incomplete
differentiation of some of the cells present in our cultures might
have resulted in the formation of small numbers of cells of the
hepatic lineage.
In conclusion, the present study shows that PTD-TFs can be
added to ES cell cultures in a dose and temporal dependent
manner. This strategy may provide important insights into the role
of TFs in the differentiation of ES cells towards pancreatic
lineages, and may inform strategies towards obtaining a more
differentiated b-cell in vitro. However, as seen in our related study
on the reprogramming of AR42-J exocrine cells [28], PTD-TFs
are unlikely to play a major role in generating ES-derived islet cells
for therapeutic purposes, because of the low levels of insulin
expression obtained when compared with mature b-cells.
Supporting Information
Figure S1 PTD-TFs are efficiently taken up by DE-
derived ES cells. (A) Immunocytochemistry of definitive
endoderm (DE) differentiated cells. Untreated (N/A) cells and
cells incubated with Pdx1 or TAT-MafA for a period of 4 hours
were stained with antibodies against the DE marker Sox17 and the
pancreatic transcription factors Pdx1 or MafA. Top panels show
staining for the nuclear marker DAPI, Sox17, Pdx1 and MafA in
DE differentiated cells which were not incubated with the PTD-
TFs (a–i). Bottom panels show staining for the nuclear marker
DAPI, Sox17, Pdx1 and MafA in DE differentiated cells which
were incubated with Pdx1 and TAT-MafA for a period of 4 hours
(j–r). Data are representative of triplicate experiments. (B) Total
and nuclear protein uptake was assessed by counting the positive
cells from triplicate cultures, where n=300 cells/replicate. Data
are expressed as mean 6 SEM.
(TIF)
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